This week in therapeutics




Licensing status

Publication and contact information


Brain cancer

H3 histone family 3A
(H3.3A; H3F3A); histone cluster 1 H3b (HIST1H3B); polycomb repressive complex 2 (PRC2)

In vitro and cell culture studies identified gain-of-function mutations in H3F3A and HIST1H3B that could be targeted to treat pediatric glioblastoma. The K27M mutation in either H3F3A or HIST1H3B is found in almost 80% of diffuse intrinsic pontine gliomas (DIPGs), a type of pediatric brain cancer. In a series of cell culture and in vitro assays, the K27M mutation was identified as a gain-of-function mutation that conferred the ability to inhibit PRC2. Next steps could include screening for compounds that inhibit the DIPG-associated mutant proteins.

SciBX 6(14); doi:10.1038/scibx.2013.331
Published online April 11, 2013

Patent and licensing status unavailable

Lewis, P.W. et al. Science; published online March 28, 2013;
Contact: C. David Allis, The Rockefeller University, New York, N.Y.